



Practitioner's Docket No. 701826-051150

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

RECEIVED

OCT 31 2002

In re application of: Paolo Renzi

Application No.: 09/719,737

Filed: 06/29/2001

For:

Group No.: 1635

Examiner: Karen A. Lacourciere

ANTISENSE OLIGONUCLEOTIDES FOR TREATING ATOPIC DISEASES
AND NEOPLASTIC CELL PROLIFERATION

TECH CENTER 1600/2900

#10/K.T.
#11/3

ELECTION

CERTIFICATE OF MAILING (37 C.F.R. SECTION 1.8(a))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

10/24/2002
Date

Nicole M. Gignac
(type or print name of person mailing paper)

Nicole M. Gignac
Signature of person mailing paper

Assistant Commissioner for Patents
Washington D.C. 20231

RESPONSE TO RESTRICTION REQUIREMENT

In response to the Restriction Requirement mailed on September 24, 2002, Applicant elects Group III (claims 41-76) with traverse, drawn to a composition comprising an antisense oligonucleotide targeted to a common subunit of IL-3, IL-5 and GM-CSF receptors (SEQ ID NO:9) and an oligonucleotide targeted to a common subunit of IL-4 and IL-13 receptors (SEQ ID NO:2) and an oligonucleotide targeted to a nucleic acid encoding a CCR3 receptor (SEQ ID NO:18). The specific species of sequences are identified in brackets by their respective SEQ ID Nos.